Virtual Library
Start Your Search
L. Koubkova
Author of
-
+
P2.03 - Chemotherapy/Targeted Therapy (ID 704)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.03-023 - Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic (ID 8732)
09:30 - 09:30 | Author(s): L. Koubkova
- Abstract
Background:
From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, erlotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment.
Method:
Only patients with EGFR mutations and in which 1st line treatment started in October 2013 and later were included in analysis. With respect to defined inclusion criteria. We analysed 287 patients (gefitinib - 138 patients, afatinib - 102 patients, erlotinib - 40 patients.). Descriptive statistics and frequency tables were used to characterize the sample data set. Statistical significance of differences among three TKI inhibitors subgroups was assessed using the Fisher’s exact test or Kruskal-Wallis test for continuous variables. Overall survival (OS) was defined as the time from 1st line TKI inhibitor treatment initiation to the date of death due to any cause. Progression-free survival (PFS) was defined as the time from 1st line TKI inhibitor treatment initiation to the date of first documented progression or death due to any cause. OS and PFS were estimated using Kaplan-Meier method and all point estimates include 95% confidence intervals (95% CI). All statistical tests were performed at a significance level of α=0.05.
Result:
Between these three groups of patients there was no statistically significant difference in sex (p=0.972), in age (p=0.031), in smoking habits (p=0.877), in type of EGFR mutation (p=0.437), in adenocarcinoma proportion (p=0.07). Between these three groups, there was statistically significant difference according to performance status (< 0.001), patients treated with afatinib have better PS in common. Between these three groups, there was no statistically significant difference according to disease control (CR+PR+SD) (p=0.626) and in response to treatment (CR + PR) (p = 0.791). There was no statistically significant difference in PFS survival (p=0,015) and in overall survival ((p=0.046). There was no statistically significant difference in the occurrence of adverse events (p=0.002).
Conclusion:
We have not found any important difference in basic characteristic of patients treated in 1st line treatment with TKI (sex, age, smoking, histology and type of EGFR mutations). We have not found any important difference in response to treatment, in disease control, PFS, in overall survival and in occurrence of adverse events. We found a significant difference in PS segmentation at treatment initiation – patients treated with afatinib have better PS than others.
